PURPOSE 2 STUDY

Could the future of PrEP be just two injections per year? Help us find out.

Even though a variety of prevention options exist, HIV remains a serious health concern for many people around the world. PURPOSE 2 will test whether an investigational PrEP (pre-exposure prophylaxis) medicine, lenacapavir, helps reduce the chance of getting HIV through sex.

This study is full and no longer accepting participants, but we can still help you get PrEP. Please request an appointment online or call 203-903-8308 for assistance over the phone.

For more information, please call 203-903-8308, email clinicaltrials@ahicorp.org, or visit PURPOSE 2’s website page.

clinicaltrials.gov identifier: NCT04925752

A model in purple light subtly smiling at the camera.